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ABSTRACT 
The continuously growing complexity of nanodrugs urges for complementary characterization 
techniques which can elude the current limitations. In this paper, the applicability of continuous 
contrast variation in small-angle X-ray scattering (SAXS) for the accurate size determination of a 
complex nanocarrier is demonstrated on the example of PEGylated liposomal doxorubicin 
(Caelyx®). The mean size and average electron density of Caelyx® was determined by SAXS 
using a gradient of aqueous iodixanol (Optiprep®), an iso-osmolar suspending medium. The 
study is focused on the isoscattering point position and the analysis of the Guinier region of the 
scattering curves recorded at different solvent densities. An average diameter of (69 ± 5) nm and 
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electron density of (346.2 ± 1.2) nm-3 was determined for the liposomal formulation of 
doxorubicin. The response of the liposomal nanocarrier to increasing solvent osmolality and the 
structure of the liposome-encapsulated doxorubicin after the osmotic shrinkage of the liposome 
are evaluated with sucrose contrast variation in SAXS and wide-angle X-ray scattering (WAXS). 
In case of using sucrose as contrast agent, a clear osmolality threshold at 670 mOsm kg-1 was 
observed above which the liposomal drug carriers start to shrink, though preserving the 
intraliposomal doxorubicin structure. The average size obtained by this technique is smaller than 
the value measured by dynamic light scattering (DLS), though this difference is expected due to 
the hydrodynamic size of the PEG moieties attached to the liposomal surface, which are not 
probed with solvent contrast variation in SAXS. The advantages and drawbacks of the proposed 
technique are discussed in comparison to DLS, the most frequently used sizing method in 
nanomedicine. 
 
Introduction 
The application of nanoparticles (NPs) in medicine opened the continuously growing field of 
nanomedicine.1–5 The first approved nano-drug was Doxil® (Caelyx® in Europe), a PEGylated 
liposomal formulation of doxorubicin, which was followed by a few other products.6,7 Nowadays 
there are approximately 250 nanomedicine products that are either approved by the relevant 
health agencies or are under clinical trials.8 On the other hand, there is a translational gap 
between the experimental work devoted to the development of new nano-drug candidates and the 
clinical realization of their use, which is also reflected in the high number of studies dealing with 
nanomedicine and the number of approved products on the market.9,10 As highlighted in a recent 
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review by Khorasani et al. one of the main reasons for this translational gap is that the current 
characterization techniques possess limitations and there is a need for standardization on this 
field.9 Among many relevant physicochemical properties of nano-drugs, one of the most 
important to be accurately determined is the size of the nanocarriers, which directly relates to the 
in vivo biodistribution of the drug. The ultimate goal in this regard is to reach a ‘traceable size 
determination’ of the nanomaterial, which means that the measurand can be related to the SI unit 
‘meter’ through an unbroken chain of comparisons with known uncertainties. The most widely 
used technique for size determination in the field of nanomedicine is dynamic light scattering 
(DLS), which measures the hydrodynamic diameter of the nanoparticles (NPs).11–16 DLS is well-
established and has indisputable advantages in the size characterization of the NPs, e.g. easy-to-
use instrumentations, fast and low-cost operation, but it is not capable of a traceable size 
determination as there is no general relationship between the hydrodynamic diameter and the 
physical size of the NPs.17 Transmission electron microscopy (TEM) is also frequently used for 
sizing of NPs and proved to be an appropriate technique for solid nanoparticles, whilst its 
employment in soft matter NPs (e.g. liposomes, micelles and polymeric nanoparticles) is 
questionable due to the possible distortion of the particles during the drying process.  Although 
cryo-TEM could overcome this limitation,18 the statistical accuracy of this non-ensemble method 
is usually not sufficient.  
This paper describes a novel approach in small-angle X-ray scattering (SAXS) to assess the 
size of a complex liposomal drug. SAXS is based on the elastic scattering of X-ray photons by 
the sample’s electrons at low angles. In contrast to protein crystallography or wide-angle X-ray 
scattering (WAXS), where the material is characterized at the atomic length scale by collecting 
the scattering pattern at wide angles, SAXS can provide structural information on nanomaterials 
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in the 1 nm to 300 nm size range. Moreover, SAXS is capable of traceable size determination for 
sufficiently monodisperse nanoparticles.17 In order to perform accurate SAXS measurements, 
monochromatic, highly collimated X-ray radiation is required with a wavelength below 1 nm, 
which is perfectly suited to probe materials on the nanoscale. The forward scattered radiation is 
recorded at small angles (typically up to 3°) with a large area pixel detector placed at a variable 
distance from the sample (usually from 1 m to 5 m). The one-dimensional scattering intensity 
curve as a function of the scattering angle is obtained by radial averaging of the two dimensional 
scattering pattern. In SAXS, the structural properties of the nanomaterials are obtained either 
from the integral scattering parameters (e.g. Guinier radius, isoscattering point) or by fitting to 
the scattering curves a known analytical model related to the measured object. 
The use of SAXS in liposome research is widespread. For instance, it has been applied to 
characterize the lamellarity, bilayer thickness, area per lipid ratio19–21 and the thickness of the 
PEG-layer of different liposomal samples22–25, also to describe the influence of extrusion on the 
average number of bilayers26 and to determine the electron density profile of liposomes20,21,27 and 
biological vesicles28.    
Despite SAXS being a usual method of choice for the accurate size determination of 
nanomaterials, the interpretation of the scattering curves, i.e. the uniqueness of the solution of the 
model fitting, is frequently intricate for complex samples. Liposomal drugs belong to this class, 
as the inner structure of the phospholipid bilayer and the incorporated drug also contribute to the 
scattering intensity. Presumably this difficulty explains the absence of SAXS studies determining 
the overall size of liposomal drugs. In general, SAXS characterization of NPs with a broad size 
distribution, a heterogeneous composition or with a complicated inner structure require either a 
priori knowledge about the morphology of the sample or the measurement of complementary 
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scattering curves obtained under different experimental conditions. Solvent contrast variation in 
SAXS belongs to the latter approach as it is based on the variation of the scattering curves 
caused by the addition of a suitable contrast agent to the suspending medium. Recording the 
scattering data as a function of the adjusted contrast enables the derivation of the mean outer size 
of the particles irrespective of their inner structure and delivers more detailed information about 
the NPs composition as compared to single-contrast measurements. In this paper we present an 
accurate description of a commercially available liposomal doxorubicin sample, which is already 
in clinical use, with a novel approach to SAXS contrast variation.29 By creating a solvent density 
gradient within a capillary, a continuous range of contrasts becomes available, which enables the 
detailed study of the mean size of the drug carrier, its structural behaviour under different 
solvents and the nature of the osmotic shrinkage of the liposomal nanocarrier. 
Materials and methods 
Materials and density gradient preparation  
The PEGylated liposomal formulation of doxorubicin, Caelyx® (SP Europe, Brussels, 
Belgium), was purchased from Hungaropharma Ltd. Caelyx® (or Doxil® in US) consist of 
liposomes formed by fully hydrogenated soy phosphatydilcholine (HSPC), cholesterol, and 
DSPE-PEG2000 (N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-
phosphoethanolamine). The latter results a steric barrier at the liposomal surface due to the PEG 
2000 residues. Doxorubicin is encapsulated in Caelyx® via an active loading procedure, which 
results a crystal-like doxorubicin precipitate inside the liposomes, as depicted schematically in 
Fig. 1.  
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The solvent density gradient was prepared in vacuum-proof borosilicate glass capillaries from 
Hilgenberg (Malsfeld, Germany) with a rectangular cross section of (4.2 ± 0.2) x (1.25 ± 0.05) 
mm2, a length of (80 ± 0.5) mm and a wall thickness of ca. 120 µm. The bottom end of the 
capillary was closed by welding and the lower section, up to a height of ca. 1 cm, was filled with 
Galden® PFPE SV90 from Solvay Plastics (Brussels, Belgium). This fluid has an exceptionally 
high density of 1.69 g/cm3, low viscosity and is immiscible with aqueous solutions. 
Consequently, a uniform interface with the particle suspension is formed at the bottom which 
serves as reference for the transmittance measurements. The suspending medium contrast 
variation study was performed with the iso-osmolar contrast agent Optiprep® (an aqueous 
solution of iodixanol), which has an osmolality of 290 to 310 mOsm kg-1. The suspending 
medium density gradient was achieved by bringing together two mixtures of different densities: 
For the bottom of the capillary, a high density mixture of Caelyx® with Optiprep™ was 
prepared with an Optiprep™ mass fraction of 35 % and a corresponding solvent electron density 
of 365.2 nm-3, whilst on the top side of the capillary a low density preparation of Caelyx®  using 
phosphate buffered saline solution (pH 7.4) with the same volume fraction of Caelyx® was 
introduced, with a solvent electron density of 341.9 nm-3. By employing Optiprep™ as a contrast 
agent, the osmolality is constant along the capillary.  
In order to study the effects of the suspending medium osmolality in the liposomal drug 
carrier, another capillary with a density gradient was created by introducing a dense aqueous 
sucrose solution with 37.8 % sucrose mass fraction (Sigma-Aldrich, Missouri, USA) at the 
bottom of the capillary (which corresponds to an electron density of 381.1 nm-3 and a solvent 
osmolality of 1775.6 mOsm kg-1), whereas a lighter solution was produced without sucrose by 
adding pure water to get the same Caelyx® concentration. Considering the sucrose mass fraction 
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of the Caelyx® buffer to be 10%, this latter preparation has an electron density of 339.4 nm-3 and 
an osmolality of 151.1 mOsm kg-1. For the wide-angle X-ray scattering measurements, a density 
gradient capillary was prepared using a denser aqueous solution with a sucrose mass fraction of 
34% and a lighter one with 6%. 
Small and Wide-angle X-Ray Scattering 
The scattering experiments were performed at the four-crystal monochromator beamline of 
PTB30 supplemented by the SAXS setup of Helmholtz-Zentrum Berlin31 at the synchrotron 
radiation facility BESSY II (Helmholtz-Zentrum Berlin, Germany). After the gradient was 
created within the capillary, the sample was moved in steps of 0.5 mm along the central vertical 
axis of the capillary and a scattering pattern was measured at each position with an exposure time 
of 60 seconds. At these positions, the solution transmittances were also measured and the 
suspending medium electron density calibrated as described elsewhere.29 The momentum 
transfer q of the scattering curves was calculated from the expression q = 4π·sinθ·E/hc where θ 
is half of the scattering angle, E = (8000.0 ± 0.8) eV is the energy of the incoming X-ray 
radiation, h is the Planck constant and c is the speed of light. The scattered X-ray photons were 
collected with a vacuum-compatible Pilatus 1M hybrid-pixel detector (Dectris Ltd, 
Baden,Switzerland) with a pixel size of d = (172.1 ± 0.2) µm at a distance L = (4575 ± 1) mm 
from the capillaries.32 The obtained scattering curve was normalized to the exposure time, the 
measured suspension transmittance and the incident photon flux, measured by means of a 
calibrated transparent silicon diode. A wide-angle configuration was employed to observe the 
diffraction peak of the fiber-like doxorubicin precipitate encapsulated in the liposomes. At this 
configuration, the sample-to-detector distance was reduced to L = (569 ± 1) mm and as a result 
the available q-range was extended until 5.55 nm-1. The X-ray transmission measurements at the 
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aqueous sucrose gradient were performed at a lower incident photon energy E = 5500 eV to 
increase the transmittance differences for the less absorbing sucrose solution by a factor of 5. 
Results and Discussion 
SAXS curves of the liposomal doxorubicin sample measured at different suspending medium 
electron densities are shown in Fig. 2. In the scattering curves, it is possible to observe the 
variation of the curve features through the increase of the suspending medium density, which 
indicates the complexity of the internal structure of the nanocarrier. Besides, the appearance of 
an intersection point around q = 0.12 nm-1 is a further indicator of the structural complexity of 
the drug-carrier. 
The solvent background has been subtracted by measuring the scattering curves of a density 
gradient of Optiprep® and buffer without nanocarriers. The low scattering power of the 
PEGylated liposomal doxorubicin at high q values and the contribution of the iodixanol 
background  result in an increased uncertainty in the high-q range of the corrected scattering 
curves, although in the Fourier region below q = 0.3 nm-1 the background effect is almost 
negligible. 
In the low q part of the scattering curve, an isoscattering point33 is clearly visible as 
highlighted in Fig.2, where all the scattering curves intersect at one point. The volume of the 
liposomal carrier remains constant along the aqueous iodixanol capillary. This assumption is 
proven by the constant intensity at the isoscattering point for this contrast agent, in comparison 
with the changes observed with sucrose as contrast agent due to the volume variation (shrinkage) 
of the liposomal carrier, which is discussed in details in the next section. The isoscattering point 
position relates directly to the external radius of the measured particle inaccessible to the solvent, 
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as explained in the Supplementary Information. Therefore, the PEG-chains attached to the 
liposome surface might not be quantified in this approach due to the permeability of the polymer 
layer. The isoscattering point position is precisely determined by calculating the relative standard 
deviation of all the scattering curves at each q-value, as shown in the inset of Fig.2. The first 
isoscattering point q*1 is located at q*1 = 0.123 nm-1, which corresponds to a radius of R = 36.5 
nm and a diameter of 73 nm. A second isoscattering point at q*2 = 0.25 nm-1 is still visible, 
although the diffuseness of the isoscattering points at higher q values, related with the 
polydispersity of the ensemble33, makes it less reliable for the determination of the outer radius. 
The determination of the q values have an associated relative uncertainty of 0.1 %, which 
corresponds to a size uncertainty of 0.6 nm. Furthermore, the radial integration of the scattering 
pattern was performed choosing a q-bin of size 0.0015 nm-1, with an associated uncertainty in the 
size of 0.9 nm. Without further considerations, the Caelyx® size uncertainty associated to the 
determination of the q-value of the isoscattering point is 1.1 nm. Other possible sources of 
uncertainty arise from the polydispersity degree of the sample and the ellipticity of the 
doxorubicin loaded liposomes, which might shift the measured position of the isoscattering 
point, although the uncertainty associated to them cannot be easily quantified.  
In order to provide a traceable uncertainty for the obtained size value, we have used an 
alternative evaluation procedure, namely the calculation of the so-called shape factor34,35 which 
extracts all contributions from the 30 measured scattering curves that change with the contrast at 
different solvent densities. The shape factor of the Caelyx® sample contains essentially 
information only about the shape and size distribution of the space filled up by the liposomes, i.e. 
the contributions of the phospholipid bilayer and the encapsulated doxorubicin to the scattering 
intensity are cancelled.  Thus, the complex interpretation of the original SAXS curve of Caelyx® 
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is avoided and enables the size determination of the liposomal carrier by fitting a simple 
analytical model for homogeneous spherical objects. A model with a certain ellipticity was also 
attempted, due to the slight liposomal eccentricity observed in TEM images6 though the best fit 
was accomplished with a spherical model. Details on the calculation of the shape factor as well 
as the analytical expression for the model fitting can be found in the Supplementary Information. 
The shape factor calculated from the SAXS curves and the theoretical model fitting are depicted 
in Fig. 3. The mean diameter obtained from the spherical form factor fit is (65.5 ± 4.7) nm, 
slightly smaller than the value calculated from the isoscattering point position. Nevertheless, 
both values overlap when considering the associated standard uncertainties and that the 
polydispersity smearing of the isoscattering point is difficult to quantify. The latter fact is 
supported by the broad size distribution determined by the shape factor fitting. When assuming a 
Gaussian size distribution, the polydispersity degree (defined as the full width at half maximum 
of the size distribution divided by its mean value) of the nanocarrier is ca. 40%. Therefore, the 
average value of (69 ± 5) nm can be embraced as a reliable external size for the liposomal drug-
carrier. 
The average size obtained by contrast variation in SAXS is smaller than the result obtained 
with DLS of ca. 86 nm (in-house measurement), which can be attributed to the fact that the DLS 
measurand is the hydrodynamic size of the nanoparticles, while SAXS provides the size of the 
spherical volume inaccessible to the solvent. As the 2 kDa PEG-chains attached to the surface of 
the liposomes contribute to the hydrodynamic radius but that layer is permeable to the solvent 
and, therefore, invisible to contrast variation SAXS, the ca. 15 nm difference between the sizes 
determined by DLS and SAXS is justified.  
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At low q-values, the Guinier approximation can be used as explained in the Supplementary 
Information. By fitting the spherical form factor to the q-range just below the first minimum of 
the scattering curves, an extrapolated value for the intensity at zero-angle I(0) could be obtained 
as displayed in Fig. 4. The minimum of the parabola fitted to the experimental points determines 
the average electron density of the drug carrier system, according to the equation I(0) ~ (ρ0-
ρsolv)2.36 From this calculation, a value of ρ0 = (346.2 ± 1.2) nm-3 is obtained which corresponds 
to the density of the liposomal nanocarrier and the precipitated drug combined. The uncertainty 
of 1.2 nm-3 is associated with the vertical size of the focused X-ray beam. The obtained density is 
slightly higher than the value of 338 nm-3 estimated for empty PEGylated liposomes37 due to the 
presence of the doxorubicin-sulfate aggregate in the intraliposomal volume.  
Due to the constant osmolality of the suspending medium along the whole density gradient, no 
osmotic pressure effects were observed in the size or density of the liposomal system. 
Nevertheless, the importance of the buffer osmotic effects in the liposomal structure cannot be 
neglected and a thorough study will be discussed in the following section. 
Effect of increasing solvent osmolality by an aqueous sucrose gradient 
The osmotic behavior of liposomes depends, basically, on their size and chemical composition. 
Larger liposomes tend to be osmotically active38 and, in this case, intraliposomal osmolality 
should be equal to the buffer outside of the liposomes. Nevertheless, the small size of Caelyx® 
and the doxorubicin-sulfate aggregate in the intraliposomal volume create an extraordinary 
resistance against the buffer osmotic pressure. This effect can be studied by increasing 
systematically the osmolality of the suspending medium, e.g. increasing the sucrose 
concentration in the aqueous buffer. 
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By means of the density gradient technique, scattering curves of the liposomal doxorubicin 
were recorded at different sucrose concentrations of the suspending medium, i.e. at different 
buffer osmolalities, as shown in Fig.5. The X-ray scattering measurements were performed at 
two different detector-to-sample distances, as described in the Materials and methods section, in 
order to study a broader q-range, spanning from 0.03 to 5.55 nm-1, and observe the 1,0-
diffraction peak of the doxorubicin fiber-like precipitate around q = 2.3 nm-1 39, as depicted in the 
inset of the Fig. 5 after proper background correction. 
As discussed in the previous section, by increasing the electron density of the suspending 
medium, the scattering curves of the drug carrier change drastically due to contrast variation. In 
the case of the aqueous sucrose gradient shown in Fig. 5, this effect is also observed and strongly 
resembles the curves measured with the Optiprep® density gradient depicted in Fig.2. 
Nevertheless, upon a certain sucrose concentration (reddish colored curves in Fig. 5), the features 
of the scattering curves disappear abruptly, because the suspending medium osmolality is so high 
that it induces morphological changes in the liposomal structure and, consequently, the scattering 
form factor of the particles changes. 
This effect can be quantified by examining the intensity of the first isoscattering point at q*1 = 
0.123 nm-1, because the scattered intensity at this point should be independent of the electron 
density of the solvent, as observed with the Optiprep® gradient. The isoscattering point intensity 
as a function of the suspending medium osmolality is shown in Fig. 6 and there is a clear 
osmolality threshold at 670 mOsm kg-1. Above this threshold, the osmotic pressure at the 
liposomal bilayer is so high that the liposome starts shrinking and changes its size, structure and, 
consequently, scattering form factor. The increased resistance against osmotic pressure, more 
than double the blood plasma osmolality and much higher than the osmolality needed to shrink 
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empty PEGylated liposomes,40 is explained by the encapsulation of doxorubicin inside the 
liposome. 
The large osmotic pressure produces a reversible shrinkage of the liposome though it is not 
capable of cracking it. This was proved in an additional experiment by increasing the osmolality 
of the buffer to 1333.6 mOsm kg-1 with a sucrose mass fraction of 31.4% and then reducing it to 
565.4 mOsm kg-1 by adding distilled water. The solvent with high osmolality produced a 
featureless scattering curve, as expected from Fig. 5, whereas, after reducing the osmotic 
pressure, the scattering curve was the same as the measured Caelyx® curve with the 
corresponding electron density, which gives evidence that the osmotic shrinkage process is 
reversible. 
The behavior of the nano-drug for an increasing solvent osmolality can be further studied by 
evaluating the crystal structure of the doxorubicin aggregate, represented by the diffraction peak 
observed in the inset of figure Fig. 5. The position of the peak in the reciprocal space depending 
on the suspending medium osmolality is depicted in Fig. 6 and shows that its position deviates 
less than 1% from the weighted average q = 2.28 nm-1 along the whole osmolality range. This 
proves that the fiber-like structure of the drug inside the liposome is also constant during the 
osmotic shrinkage of the liposomes. The measured position of the 1,0 diffraction peak matches 
exactly the value measured from doxorubicin-sulfate complexes in solution.41 
To conclude this section, the diameter obtained from the isoscattering position in the aqueous 
iodixanol solution can be compared with what is measured in an aqueous sucrose suspending 
medium.  In the latter, if only the scattering curves below this osmolality threshold are 
considered, the relative standard deviation for each q value reveals a pronounced minimum for 
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the first isoscattering point as depicted in Fig. 7. When comparing this result with the relative 
standard deviation curve obtained from the Optiprep® contrast variation measurements, both 
values for the size of the drug carrier agree remarkably well within 0.8 %. This reflects the 
independence of the technique from the contrast agent added to the suspending medium and 
shows the repeatability of the results. 
Conclusion 
This article demonstrates that it is possible to determine the size of a PEGylated liposomal 
drug carrier with continuous contrast variation in SAXS. By means of an iso-osmolal density 
gradient, the position of the isoscattering point was measured whereby the size of the liposomal 
drug was determined. Supplemented by the model fitting of the so called shape factor of the 
liposomes, the size was also obtained from an independent evaluation procedure and an average 
size of (69 ± 5) nm was obtained. This size is smaller than the value measured by DLS, which 
can be attributed to the fact that the contrast variation SAXS determines the size of the liposomes 
impermeable to the contrast agent, i.e. the outer PEG layer of the liposomes is not probed. The 
latter implies that the combination of SAXS with DLS can reveal the difference between the 
hydrodynamic diameter and the “core” size of the nanocarrier, which is related to the thickness 
of the PEG-layer in case of stealth liposomes. Moreover the method presented in this paper 
shows that by means of the shape factor fitting, complementary information about the shape of 
the nanocarrier can be obtained. 
Using an aqueous sucrose density gradient, it was shown that an increasing osmolality of the 
buffer produces an osmotic shrinkage of the liposomal structure, although this structural 
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deformation is reversible and does not affect the crystalline structure of the intraliposomal 
doxorubicin. 
These results, together with the determination of the average electron density of the liposomal 
doxorubicin of (346.2 ± 1.2) nm-3, demonstrate the applicability of the density gradient technique 
for complex particles. This model-free approach to contrast variation in SAXS proves to be a 
powerful sizing technique, which, in addition, makes it possible to study simultaneously the 
behavior of the liposomal drug carrier under different osmotic conditions. 
FIGURES 
Figure 1. Schematic representation of the PEGylated liposomal doxorubicin morphology. 
Figure 2. Scattering curves at different suspending medium electron densities obtained with a 
solvent density gradient of Caelyx® in aqueous iodixanol with constant buffer osmolality. The 
inset shows the precise position of the isoscattering points.  
Figure 3. The shape factor of the liposomes obtained from the experimental data is shown with 
black circles and the model fit for homogenous spherical particles is depicted in red. 
Figure 4. Measured intensity at zero-angle of Caelyx® as a function of the electron density of 
the aqueous iodixanol suspending medium. The function fitted to the experimental data is 
depicted in black. 
Figure 5. Scattering curves of Caelyx® in an aqueous sucrose density gradient calibrated to the 
osmolality of the suspending medium. In the inset, the q-region where the doxorubicin 
diffraction peak appears can be observed. 
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Figure 6. The intensity of the first isoscattering point depending on the aqueous sucrose solution 
osmolality is shown with black dots. With red symbols, the shift of the doxorubicin-aggregate 
diffraction peak is displayed. 
Figure 7. Isoscattering point position quantified by the calculation of the relative standard 
deviation of the scattering curves for different solvent density gradients. In the case of the 
aqueous sucrose solution (black line), only the scattering curves below the osmolality threshold 
were employed for the calculation. 
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Continuous contrast variation in small-angle X-ray scattering (SAXS) was used for the accurate 
size determination of PEGylated liposomal doxorubicin (Caelyx®). The mean size and average 
electron density of Caelyx® was determined by SAXS using a gradient of aqueous iodixanol 
(Optiprep®), an iso-osmolar suspending medium. Moreover, the response of the liposomal 
nanocarrier to increasing solvent osmolality and the structure of the liposome-encapsulated 
doxorubicin after the osmotic shrinkage of the liposome were evaluated with sucrose contrast 
variation in SAXS and wide-angle X-ray scattering (WAXS). 
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